U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H22N4O6S
Molecular Weight 458.4895
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RALTITREXED

SMILES

Cc1nc2ccc(cc2c(n1)O)CN(C)c3ccc(C(=O)N[C@@]([H])(CCC(=O)O)C(=O)O)s3

InChI

InChIKey=IVTVGDXNLFLDRM-HNNXBMFYSA-N
InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/21148615

Raltitrexed belongs to a group of medicines known as antimetabolites. It is used to treat cancer of the colon and rectum. It may also be used to treat other kinds of cancer, as determined by your doctor. Raltitrexed blocks an enzyme needed by the cell to live. This interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by raltitrexed, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Raltitrexed inhibits thymidylate synthase (TS) leading to DNA fragmentation and cell death. It is transported into cells via a reduced folate carrier. Inside the cell Raltitrexed is extensively polyglutamated, which enhances thymidylate synthase inhibitory power and duration. Inhibition of this enzyme results in decreased synthesis of thymidine triphosphate which is required for DNA synthesis. Raltitrexed is used for the treatment of malignant neoplasm of colon and rectum. Although raltitrexed is not approved by the US FDA, the drug was licensed in Canada and some European countries.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
530 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Tomudex

Approved Use

The palliative treatment of advanced colorectal cancer where 5-Fluorouracil and folinic acid based regimens are either not tolerated or inappropriate.

Launch Date

961804800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
567.1 ng/mL
3 mg/m² 1 times / day other, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: OTHER
co-administered:
RALTITREXED blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
736.8 ng/mL
3 mg/m² single, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RALTITREXED plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1547.9 ng × h/mL
3 mg/m² 1 times / day other, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: OTHER
co-administered:
RALTITREXED blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2341.7 ng × h/mL
3 mg/m² single, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RALTITREXED plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
3 mg/m² 1 times / day other, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: OTHER
co-administered:
RALTITREXED blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 min
3 mg/m² single, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
RALTITREXED plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
RALTITREXED plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
DLT: Asthenia, Granulocytopenia...
Other AEs: Leukocytopenia, Nausea...
Dose limiting toxicities:
Asthenia (grade 3, 33.3%)
Granulocytopenia (grade 4, 11.1%)
Fatigue (grade 3, 11.1%)
Other AEs:
Leukocytopenia (grade 3, 11.1%)
Nausea (grade 3, 11.1%)
Aspartate aminotransferase increased (grade 3, 11.1%)
Alanine aminotransferase increase (grade 3, 33.3%)
Bilirubin elevated (grade 3-4, 11.1%)
Sources:
3.5 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
DLT: Asthenia...
Other AEs: Decreased hemoglobin...
Dose limiting toxicities:
Asthenia (grade 3, 15.4%)
Other AEs:
Decreased hemoglobin (grade 3, 7.7%)
Sources:
4 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
DLT: Granulocytopenia, Bilirubin elevated...
Dose limiting toxicities:
Granulocytopenia (grade 4, 16.7%)
Bilirubin elevated (grade 4, 8.3%)
Sources:
2.5 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 2.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 62 years
Health Status: unhealthy
Age Group: Median age 62 years
Sex: M+F
Sources:
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 66.7%)
Sources:
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
unhealthy
DLT: Leukocytopenia, Transaminases increased...
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Other AEs: Nausea and vomiting, Diarrhea...
Other AEs:
Nausea and vomiting (grade 3-4, 11.6%)
Diarrhea (grade 3-4, 11.1%)
Constipation (grade 3-4, 2%)
Oral soft tissue conditions (grade 3-4, 2.1%)
Pain (grade 3-4, 7.3%)
Infection (grade 3-4, 5%)
Hemoglobin decreased (grade 3-4, 6.5%)
Thrombocytopenia (grade 3-4, 3.5%)
Blood bilirubin decreased (grade 3-4, 2.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Aspartate aminotransferase increased grade 3, 11.1%
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Leukocytopenia grade 3, 11.1%
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Nausea grade 3, 11.1%
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Fatigue grade 3, 11.1%
DLT
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Alanine aminotransferase increase grade 3, 33.3%
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Asthenia grade 3, 33.3%
DLT
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Bilirubin elevated grade 3-4, 11.1%
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Granulocytopenia grade 4, 11.1%
DLT
4.5 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose|MTD
Dose: 4.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Asthenia grade 3, 15.4%
DLT
3.5 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Decreased hemoglobin grade 3, 7.7%
3.5 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Granulocytopenia grade 4, 16.7%
DLT
4 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Bilirubin elevated grade 4, 8.3%
DLT
4 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 55.5 years
Health Status: unhealthy
Age Group: Median age 55.5 years
Sex: M+F
Sources:
Neutropenia grade 4, 66.7%
DLT
2.5 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 2.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, Median age 62 years
Health Status: unhealthy
Age Group: Median age 62 years
Sex: M+F
Sources:
Transaminases increased grade 3-4, 10.1%
DLT
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
unhealthy
Leukocytopenia grade 3-4, 12.9%
DLT
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
unhealthy
Diarrhea grade 3-4, 11.1%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Nausea and vomiting grade 3-4, 11.6%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Constipation grade 3-4, 2%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Oral soft tissue conditions grade 3-4, 2.1%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Blood bilirubin decreased grade 3-4, 2.2%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Thrombocytopenia grade 3-4, 3.5%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Infection grade 3-4, 5%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Hemoglobin decreased grade 3-4, 6.5%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Pain grade 3-4, 7.3%
3 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

PubMed

PubMed

TitleDatePubMed
Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.
1999 Aug
The thymidylate synthase inhibitor ZD1694 potently inhibits murine and human cytomegalovirus replication in quiescent fibroblasts.
2000 Aug
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
2001
[New chemotherapies for colorectal cancer treatment].
2001 Apr
Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
2001 Apr 1
Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells.
2001 Apr 1
[Oxaliplatin: a first DACH-platinum in oncology].
2001 Aug
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.
2001 Feb
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
2001 Jan
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
2001 Jan
Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells.
2001 Jan
Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.
2001 Jan 1
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
2001 Jul
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
2001 Jul 15
Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
2001 Mar
A novel approach to thymidylate synthase as a target for cancer chemotherapy.
2001 Mar
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
2001 May
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
2001 Nov
Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.
2001 Nov-Dec
[New therapeutic options in chemotherapy of advanced colorectal cancer].
2001 Oct 15
[Recent aspects of palliative treatment of metastasized colorectal carcinoma].
2001 Sep 15
[Intraoperative radiotherapy (IORT) in the treatment of rectal cancer].
2001 Sep-Oct
Present indications for adjuvant therapy in resectable rectal cancer.
2001 Sep-Oct
[Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
2002
Chemotherapy in colorectal cancer: new options and new challenges.
2002
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
2002
[The rare manifestation of soft tissue metastasis in colorectal cancer].
2002
Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
2002
Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count.
2002
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
2002
Pemetrexed for diffuse malignant pleural mesothelioma.
2002 Apr
Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
2002 Aug
Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
2002 Feb
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
2002 Jan
Update on pharmacogenetics in cancer chemotherapy.
2002 Mar
Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.
2002 May
Oxaliplatin: results in colorectal carcinoma.
2002 Oct
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
2002 Oct
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.
2002 Sep
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
2002 Sep
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
2002 Sep 9
Patents

Sample Use Guides

The recommended dose is 3 mg/m2 given intravenously, as a single short, intravenous infusion in 50 to 250 ml of either 0.9% sodium chloride solution or 5% dextrose (glucose) solution. It is recommended that the infusion is given over a 15 minute period. Other drugs should not be mixed with 'Tomudex' (raltitrexed) in the same infusion container. In the absence of toxicity, treatment may be repeated every 3 weeks.
Route of Administration: Intravenous
In WiDr colon adenocarcinoma cells the cytotoxicity of 1.0 uM Raltitrexed (4 h) varied from 0% to >99% within the reported range of human serum thymidine concentrations from 500 to <50 nM, respectively.
Name Type Language
RALTITREXED
INN   JAN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
L-GLUTAMIC ACID, N-((5-(((1,4-DIHYDRO-2-METHYL-4-OXO-6-QUINAZOLINYL)METHYL)METHYLAMINO)-2-THIENYL)CARBONYL)-
Common Name English
ZD-1694
Code English
RALTITREXED [MART.]
Common Name English
RALTITREXED [JAN]
Common Name English
ZD-16
Code English
RALTITREXED [MI]
Common Name English
RALTITREXED [INN]
Common Name English
ZD1694
Code English
RALTITREXED [WHO-DD]
Common Name English
N-(5-(((3,4-DIHYDRO-2-METHYL-4-OXO-6-QUINAZOLINYL)METHYL)METHYLAMINO)-2-THENOYL)-L-GLUTAMIC ACID
Systematic Name English
RALTITREXED [USAN]
Common Name English
TOMUDEX
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C511
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
WHO-VATC QL01BA03
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
WHO-ATC L01BA03
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
NCI_THESAURUS C2021
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
Code System Code Type Description
EPA CompTox
112887-68-0
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
DRUG CENTRAL
2353
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
EVMPD
SUB10244MIG
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
FDA UNII
FCB9EGG971
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
IUPHAR
7403
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
MERCK INDEX
M9487
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
RALTITREXED
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
MESH
C068874
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
ChEMBL
CHEMBL225071
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
CAS
112887-68-0
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
PUBCHEM
135400182
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
INN
7319
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
RXCUI
196239
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB00293
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY
NCI_THESAURUS
C1804
Created by admin on Sat Jun 26 10:48:43 UTC 2021 , Edited by admin on Sat Jun 26 10:48:43 UTC 2021
PRIMARY